Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Sands

Showing results (91-100 of 513) with videos related to

Pageof 52
Sort By:
Psychopharmacology|July 4, 2008
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding studyDaniel E Casey, Earl E Sands, Jens Heisterberg, et al.
Alimentary Pharmacology & Therapeutics|May 12, 2016
Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease - authors' replyS C Shah, J-F Colombel, B E Sands, et al.
Journal of Clinical Gastroenterology|August 19, 2006
Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practiceBruce E Sands, Karl M Kilgore, Richard S Bloomfeld, et al.
Gut|July 13, 2004
Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's diseaseD G Forcione, M J Rosen, J B Kisiel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 12, 2004
Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II StudyBruce E Sands, Marion A Blank, Kam Patel, et al.
JAMA Network Open|April 13, 2023
Health Care-Associated Infections Among Hospitalized Patients With COVID-19, March 2020-March 2022Kenneth E Sands, E Jackie Blanchard, Sarah Fraker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2015
Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot?Jason M Shapiro, Judy H Cho, Bruce E Sands, et al.
The Journal of Urology|May 1, 1994
Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcomeG K Zagars, M E Sands, A Pollack, et al.
Inflammatory Bowel Diseases|July 15, 2010
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agentSreedhar Subramanian, Vijay Yajnik, Bruce E Sands, et al.
Urology|August 1, 1994
Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancerM E Sands, G K Zagars, A Pollack, et al.
Pageof 52

Showing results (91-100 of 513) with videos related to

Sort By:
Pageof 52
Psychopharmacology|July 4, 2008
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding studyDaniel E Casey, Earl E Sands, Jens Heisterberg, et al.
Alimentary Pharmacology & Therapeutics|May 12, 2016
Letter: mucosal healing is associated with improved long-term outcomes in Crohn's disease - authors' replyS C Shah, J-F Colombel, B E Sands, et al.
Journal of Clinical Gastroenterology|August 19, 2006
Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practiceBruce E Sands, Karl M Kilgore, Richard S Bloomfeld, et al.
Gut|July 13, 2004
Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's diseaseD G Forcione, M J Rosen, J B Kisiel, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 12, 2004
Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II StudyBruce E Sands, Marion A Blank, Kam Patel, et al.
JAMA Network Open|April 13, 2023
Health Care-Associated Infections Among Hospitalized Patients With COVID-19, March 2020-March 2022Kenneth E Sands, E Jackie Blanchard, Sarah Fraker, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 1, 2015
Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot?Jason M Shapiro, Judy H Cho, Bruce E Sands, et al.
The Journal of Urology|May 1, 1994
Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcomeG K Zagars, M E Sands, A Pollack, et al.
Inflammatory Bowel Diseases|July 15, 2010
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agentSreedhar Subramanian, Vijay Yajnik, Bruce E Sands, et al.
Urology|August 1, 1994
Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancerM E Sands, G K Zagars, A Pollack, et al.
Pageof 52